Keros Therapeutics (NASDAQ:KROS) Shares Down 2.7% on Analyst Downgrade

Keros Therapeutics, Inc. (NASDAQ:KROS) shares fell 2.7% during mid-day trading on Tuesday after Truist Financial lowered their price target on the stock from $100.00 to $43.00. Truist Financial currently has a buy rating on the stock. Keros Therapeutics traded as low as $16.63 and last traded at $16.65. 211,223 shares were traded during mid-day trading, a decline of 57% from the average session volume of 487,966 shares. The stock had previously closed at $17.12.

A number of other equities analysts also recently commented on KROS. TD Cowen downgraded shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Oppenheimer cut their target price on Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday, December 16th. Wells Fargo & Company upped their price target on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, Jefferies Financial Group started coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Keros Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $75.00.

Hedge Funds Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. KBC Group NV lifted its position in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new position in shares of Keros Therapeutics in the 3rd quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Keros Therapeutics during the 2nd quarter worth about $128,000. Finally, LMR Partners LLP purchased a new stake in Keros Therapeutics during the third quarter worth approximately $213,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Down 2.7 %

The stock has a market capitalization of $674.44 million, a price-to-earnings ratio of -3.20 and a beta of 1.20. The stock has a fifty day moving average of $54.10 and a 200-day moving average of $51.40.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million for the quarter. During the same quarter in the prior year, the company earned ($1.33) EPS. Keros Therapeutics’s quarterly revenue was up 4750.0% compared to the same quarter last year. On average, equities analysts forecast that Keros Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.